F.D.A. Is Said to Delay Decision on Duchenne Muscular Dystrophy Drug by ANDREW POLLACK

By ANDREW POLLACK

The news caused a sharp rise in the stock of Sarepta Therapeutics, the maker of the drug, as some investors saw a hint of approval in the development.

Published: May 26, 2016 at 12:00AM

from NYT Business Day http://ift.tt/1sPCRmQ

from WordPress http://ift.tt/1Xwvtrz
via Hadi Aboukhater